LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Home・Elenco Azioni・AbCellera Biologics Inc

AbCellera Biologics Inc

Chiusa

SettoreSettore sanitario

3.51

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.44

Massimo

3.58

Metriche Chiave
By Trading Economics
Entrata	48M -8.9M
Vendite	36M 45M
Margine di Profitto	-19.942
Dipendenti	562
EBITDA	22M -18M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+97.18% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	172M 1.1B
Apertura precedente	3.51
Chiusura precedente	3.51

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

1.99 / 2.635 Supporto e resistenza

AbCellera Biologics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mar 2026, 22:51 UTC

Utili

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mar 2026, 21:40 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mar 2026, 20:31 UTC

Utili

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mar 2026, 23:49 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mar 2026, 23:31 UTC

Discorsi di Mercato

Gold Rises on Likely Technical Recovery -- Market Talk

18 mar 2026, 22:49 UTC

Discorsi di Mercato

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mar 2026, 22:41 UTC

Discorsi di Mercato

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mar 2026, 22:36 UTC

Utili

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mar 2026, 22:24 UTC

Utili

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mar 2026, 22:23 UTC

Utili

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mar 2026, 22:23 UTC

Utili

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mar 2026, 21:58 UTC

Utili

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mar 2026, 21:55 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

18 mar 2026, 21:55 UTC

Discorsi di Mercato

Utili

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mar 2026, 21:40 UTC

Discorsi di Mercato

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mar 2026, 21:16 UTC

Discorsi di Mercato

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mar 2026, 21:00 UTC

Principali Notizie su Eventi

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mar 2026, 20:58 UTC

Utili

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mar 2026, 20:41 UTC

Utili

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:29 UTC

Utili

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:25 UTC

Utili

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:17 UTC

Utili

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mar 2026, 20:14 UTC

Discorsi di Mercato

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mar 2026, 20:09 UTC

Utili

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mar 2026, 20:07 UTC

Utili

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mar 2026, 20:06 UTC

Utili

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mar 2026, 20:04 UTC

Utili

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mar 2026, 20:04 UTC

Utili

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mar 2026, 20:04 UTC

Utili

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mar 2026, 20:03 UTC

Utili

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Confronto tra pari

Modifica del prezzo

AbCellera Biologics Inc Previsione

Obiettivo di Prezzo

By TipRanks

97.18% in crescita

Previsioni per 12 mesi

Media 7 USD 97.18%

Alto 7 USD

Basso 7 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AbCellera Biologics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a AbCellera Biologics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.99 / 2.635Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.